Omalizumab binds to free IgE, inhibiting further binding of IgE to high-affinity IgE receptors on mast cells and basophils (Brusselle and Koppelman, 2022), while IgE is considered an important part of the multi-component T2 immune response towards parasitic infections (Cooper et al., 2008; Fitzsimmons et al., 2014). Here, IGHE is linked to parasitic infectious disease.